Literature DB >> 23077310

Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting.

Erkko Ylösmäki1, Miika Martikainen, Ari Hinkkanen, Kalle Saksela.   

Abstract

Artificial target sequences for tissue-specific miRNAs have recently been introduced as a new means for altering the tissue tropism of viral replication. This approach can be used to improve the safety of oncolytic viruses for cancer virotherapy by restricting their replication in unwanted tissues, such as the liver. Semliki Forest virus (SFV) is a positive-strand RNA virus and, similar to the related alphaviruses, like Sindbis virus, has potential as a gene therapy vector and an oncolytic virotherapy agent, but this potential is limited by the neurovirulence of these alphaviruses. Here, we have generated a replicative SFV4 carrying six tandem targets for the neuron-specific miR124 between the viral nonstructural protein 3 and 4 (nsp3 and nsp4) genes. When administered intraperitoneally into adult BALB/c mice, SFV4-miRT124 displayed an attenuated spread into the central nervous system (CNS) and greatly increased survival. Peripheral replication was not affected, indicating neuron-specific attenuation. Moreover, a strong protective SFV immunity was elicited in these animals. Intracranial infection of adult mice with SFV4-miRT124 showed greatly reduced infection of neurons in the brain but led to the infection of oligodendrocytes in the corpus callosum. Taken together, our data show that miR124-mediated attenuation of neurovirulence is a feasible and promising strategy for generating safer oncolytic alphavirus virotherapy agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077310      PMCID: PMC3536368          DOI: 10.1128/JVI.01940-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides.

Authors:  Monika Deo; Jenn-Yah Yu; Kwan-Ho Chung; Melissa Tippens; David L Turner
Journal:  Dev Dyn       Date:  2006-09       Impact factor: 3.780

2.  Engineering microRNA responsiveness to decrease virus pathogenicity.

Authors:  Elizabeth J Kelly; Elizabeth M Hadac; Suzanne Greiner; Stephen J Russell
Journal:  Nat Med       Date:  2008-10-26       Impact factor: 53.440

3.  Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.

Authors:  Erkko Ylösmäki; Tanja Hakkarainen; Akseli Hemminki; Tapio Visakorpi; Raul Andino; Kalle Saksela
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

4.  miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

Authors:  Jinhong Chang; Emmanuelle Nicolas; Debora Marks; Chris Sander; Anthony Lerro; Marie Annick Buendia; Chunxiao Xu; William S Mason; Thomas Moloshok; Roque Bort; Kenneth S Zaret; John M Taylor
Journal:  RNA Biol       Date:  2004-07-01       Impact factor: 4.652

5.  Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.

Authors:  Markus J V Vähä-Koskela; Janne P Kallio; Linda C Jansson; Jari E Heikkilä; Vasily A Zakhartchenko; Markku A Kallajoki; Veli-Matti Kähäri; Ari E Hinkkanen
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

6.  Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.

Authors:  Anna Ketola; Ari Hinkkanen; Felicitas Yongabi; Petra Furu; Ann-Marie Määttä; Timo Liimatainen; Risto Pirinen; Marko Björn; Tanja Hakkarainen; Kimmo Mäkinen; Jarmo Wahlfors; Riikka Pellinen
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

7.  The Semliki Forest virus E2 gene as a virulence determinant.

Authors:  M G Santagati; J A Määttä; P V Itäranta; A A Salmi; A E Hinkkanen
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

8.  Virulence of a mouse-adapted Semliki Forest virus strain is associated with reduced susceptibility to interferon.

Authors:  Stefan A Deuber; Jovan Pavlovic
Journal:  J Gen Virol       Date:  2007-07       Impact factor: 3.891

9.  Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.

Authors:  Ann-Marie Määttä; Kimmo Mäkinen; Anna Ketola; Timo Liimatainen; Felicitas Newu Yongabi; Markus Vähä-Koskela; Risto Pirinen; Outi Rautsi; Riikka Pellinen; Ari Hinkkanen; Jarmo Wahlfors
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

10.  Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.

Authors:  Dwight Barnes; Mark Kunitomi; Marco Vignuzzi; Kalle Saksela; Raul Andino
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

View more
  29 in total

1.  Optogenetic manipulation of medullary neurons in the locust optic lobe.

Authors:  Hongxia Wang; Richard B Dewell; Markus U Ehrengruber; Eran Segev; Jacob Reimer; Michael L Roukes; Fabrizio Gabbiani
Journal:  J Neurophysiol       Date:  2018-08-15       Impact factor: 2.714

2.  Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA.

Authors:  Junwei Li; Maria T Arévalo; Diana Diaz-Arévalo; Yanping Chen; Jang-Gi Choi; Mingtao Zeng
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

3.  Targeting macrophage- and intestinal epithelial cell-specific microRNAs against norovirus restricts replication in vivo.

Authors:  Lucy Thorne; Jia Lu; Yasmin Chaudhry; Dalan Bailey; Ian Goodfellow
Journal:  J Gen Virol       Date:  2018-04-23       Impact factor: 3.891

Review 4.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 5.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

6.  MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.

Authors:  Miika Martikainen; Minna Niittykoski; Mikael von und zu Fraunberg; Arto Immonen; Susanna Koponen; Maartje van Geenen; Markus Vähä-Koskela; Erkko Ylösmäki; Juha E Jääskeläinen; Kalle Saksela; Ari Hinkkanen
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

7.  Chikungunya virus replication in skeletal muscle cells is required for disease development.

Authors:  Anthony J Lentscher; Mary K McCarthy; Nicholas A May; Bennett J Davenport; Stephanie A Montgomery; Krishnan Raghunathan; Nicole McAllister; Laurie A Silva; Thomas E Morrison; Terence S Dermody
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

8.  Silencing of neurotropic flavivirus replication in the central nervous system by combining multiple microRNA target insertions in two distinct viral genome regions.

Authors:  Natalya L Teterina; Guangping Liu; Olga A Maximova; Alexander G Pletnev
Journal:  Virology       Date:  2014-04-19       Impact factor: 3.616

9.  Generation of Self-Inhibitory Recombinant Viral Hemorrhagic Septicemia Virus (VHSV) by Insertion of Viral P Gene-Targeting Artificial MicroRNA into Viral Genome and Effect of Dicer Gene Knockout on the Recombinant VHSV Replication.

Authors:  Jun Soung Kwak; Ki Hong Kim
Journal:  Mar Biotechnol (NY)       Date:  2021-07-15       Impact factor: 3.619

10.  Infection of Aedes aegypti Mosquitoes with Midgut-Attenuated Sindbis Virus Reduces, but Does Not Eliminate, Disseminated Infection.

Authors:  Alexis Carpenter; William Bart Bryant; Scott R Santos; Rollie J Clem
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.